Hepatitis C virus inhibitors

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S307000, C546S146000, C546S139000, C546S148000, C546S149000

Reexamination Certificate

active

10992566

ABSTRACT:
Hepatitis C virus inhibitors are disclosed having the general formula:wherein R1, R2, R3, R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

REFERENCES:
patent: 5633388 (1997-05-01), Diana et al.
patent: 5866684 (1999-02-01), Attwood et al.
patent: 5869253 (1999-02-01), Draper
patent: 6018020 (2000-01-01), Attwood et al.
patent: 6225284 (2001-05-01), Albert et al.
patent: 6265380 (2001-07-01), Tung et al.
patent: 6268207 (2001-07-01), Bailey et al.
patent: 6323180 (2001-11-01), Llinas-Brunet et al.
patent: 6410531 (2002-06-01), Llinas-Brunet et al.
patent: 6420380 (2002-07-01), Llinas-Brunet et al.
patent: 6534523 (2003-03-01), Llinas-Brunet et al.
patent: 6642204 (2003-11-01), Llinas-Brunet et al.
patent: 6869964 (2005-03-01), Campbell et al.
patent: 6872805 (2005-03-01), Campbell et al.
patent: 6878722 (2005-04-01), Campbell et al.
patent: 2002/0111313 (2002-08-01), Campbell et al.
patent: 2003/0186895 (2003-10-01), Llinas-Brunet et al.
patent: 2004/0048802 (2004-03-01), Ripka et al.
patent: 2004/0077551 (2004-04-01), Campbell et al.
patent: 2004/0180815 (2004-09-01), Nakajima et al.
patent: 1162196 (2000-12-01), None
patent: WO 95/33764 (1995-12-01), None
patent: WO 97/06804 (1997-02-01), None
patent: WO 97/43310 (1997-11-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 98/46597 (1998-10-01), None
patent: WO 98/46630 (1998-10-01), None
patent: WO 99/07733 (1999-02-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 99/38888 (1999-08-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 99/64442 (1999-12-01), None
patent: WO 00/06529 (2000-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 00/13708 (2000-03-01), None
patent: WO 00/18231 (2000-04-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 01/32153 (2001-05-01), None
patent: WO 01/85172 (2001-11-01), None
patent: WO 02/04425 (2002-01-01), None
patent: WO 02/06246 (2002-01-01), None
patent: WO 02/060926 (2002-08-01), None
patent: WO 03/064416 (2003-08-01), None
patent: WO 03/064455 (2003-08-01), None
patent: WO 03/064456 (2003-08-01), None
patent: WO 03/066103 (2003-08-01), None
patent: WO 03/099274 (2003-12-01), None
patent: WO 03/099316 (2003-12-01), None
patent: WO 2004/032827 (2004-04-01), None
patent: WO 2004/043339 (2004-05-01), None
patent: WO 2005/046712 (2005-05-01), None
U.S. Appl. No. 10/985,106, filed Nov. 10, 2004, Scola et al.
U.S. Appl. No. 10/992,548, filed Nov. 18, 2004, Scola et al.
Lauer, G. M. et al., “Hepatitis C Virus Infection,” The New England Journal of Medicine, vol. 345, No. 1, pp. 41-52 (2001).
Zeuzem, S. et al., “Peginterferon Alfa-2a In Patients with Chronic Hepatitis C,” The New England Journal of Medicine, vol. 343, No. 23, pp. 1666-1672 (2000).
Poynard, T. et al., “Randomised trial of Interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus,” The Lancet, vol. 352, pp. 1426-1432 (1998).
Poupart et al., “Solid-Phase Synthesis of Peptidomimetic Inhibitors for the Hepatitis C Virus NS3 Protease,” The Journal of Organic Chemistry, vol. 66, No. 14, pp. 4743-4751 (2001).
Steinkuhler et al., “Product Inhibition of the Hepatitis C Virus NS3 Protease,” Biochemistry, vol. 37, pp. 8899-8905 (1998).
Ingallinella et al., “Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products,” Biochemistry, vol. 37, pp. 8906-8914 (1998).
Chu et al., “Structure of Sch 68631: A New Hepatitis C Virus Proteinase Inhibitor from Streptomyces sp.,” Tetrahedron Letters, vol. 37, No. 40, pp. 7229-7232 (1996).
Matsumoto et al., “3D Modeling of HCV Protease and Computer Screening of its Inhibitors,” Antiviral Research, vol. 30, No. 1, pp. A23, Abstract 19 (1996).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Hepatitis C virus inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hepatitis C virus inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus inhibitors will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3844431

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.